HéMaVie, a solution for patients suffering from multiple myeloma
Problem : improve the daily lives of patients
Multiple myeloma is a rare cancer of the bone marrow. Each year, about 5000 new cases of myeloma are detected in France. The average patient is 72-years old when diagnosed. The disease, along with its heavy treatments (chemotherapies, targeted therapies, autografts) lead to significant changes in everyday life: impact on social and family life, loss of autonomy; and impact on the quality of life (pain, anxiety, side effects). It is essential to support each patient in a reinforced and personalized manner, and to provide them with accurate and reliable information on the disease, its cause, and its progression.
Solution : a human and personalized engagement and support solution
The AF3M* and Bristol Myers Squibb, a pharmaceutical company, joined forces along a common objective: to contribute to the improvement of the multiple myeloma care pathway, and the patient experience. They called on Observia’s expertise to develop an innovative and personalized support solution called HéMaVie. HéMaVie aims to improve the lives of patients and to facilitate communication between healthcare professionals, patients, relatives, and caregivers. Via a multi-device, digital platform and a nurse coordinator, many services and tools are available night and day. HéMaVie is among the first ever human and concrete program, strongly integrated into the patient journey. Below are some examples of available services:
- Personalized coaching & nurse call support
- Social network and regional event directory
- Customized tool box & information guides
* French Association supporting patients with Multiple Myeloma
Testimony
Methods
Results
Conclusion
Thanks to a collaborative approach integrating all key stakeholders (carers, patients, nursing staff...),
HéMaVie was designed to be a comprehensive engagement and support tool. Due to Observia’s unwavering committment to customization, each patient benefits from a tailor-made program, set according to his or her preferences. Already considered a noteworthy patient initiative in France, the HéMaVie platform aims to scale up to include other disease areas within hematology and to expand to different countries. Long live HéMaVie!See also
New study results show SPUR™ tool predicts hospital admission and early readmission
Prevention Journeys and Observia partner to improve dementia prevention
SPUR as a predictor of admission and early readmission in patients living with Type 2 Diabetes
Need more information?
A burning question, a specific request, a great project to share with us? Get in touch, our teams are here to help!
